Infectious Disease Advisor | M72/AS01 TB Vaccine Shows Favorable Safety Profile in People With HIV

11 October 2026

Infectious Disease Advisor news story

The M72/AS01 TB vaccine appears to be well tolerated among people with HIV (PWH) receiving antiretroviral therapy (ART), despite higher rates of short-term local and systemic reactions compared with placebo, according to study findings published in Open Forum Infectious Diseases.

PWH continue to experience an increased burden of TB despite treatment with ART. However, evidence regarding the safety of M72/AS01 in this population has been limited. Researchers conducted a systematic review and meta-analysis to characterize adverse events associated with M72/AS01 among PWH receiving ART.

Read the full news story here.

/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/

Source: Infectious Disease Advisor